Back to Newsroom

Cellular Dynamics Issued U.S. Patent Covering iPSC Episomal Reprogramming

MADISON, Wis., Oct. 2, 2013 — Cellular Dynamics International (CDI) (Nasdaq:ICEL), announced today that the U.S. Patent and Trademark Office (PTO) issued Patent No. 8,546,140 entitled “Methods for the Production of iPS Cells Using Non-Viral Approach” on October 1. The newly issued patent relates to the method by which adult tissue cells, such as blood or skin, are reprogrammed into induced pluripotent stem (iPS) cells by the insertion of episomal vectors. This method is used by CDI for the creation of its iCell and MyCell Products. This episomal reprogramming patent has a term extending through May 2030.